Que F G, Nagorney D M
Department of Surgery, Mayo Clinic, Rochester, Minnesota 55905.
Br J Surg. 1994 Feb;81(2):255-8. doi: 10.1002/bjs.1800810234.
Hepatic resection is the only treatment for patients with colorectal cancer metastatic to the liver that has resulted in long-term survival. This apparent efficacy of hepatectomy has prompted efforts to expand the surgical approach for disease progression within the liver. A review of personal experience and of the literature was performed in an attempt to define the role of surgery for disease progression. Twenty-one patients who underwent hepatic resection between 1983 and 1991 for isolated disease progression in the liver were retrospectively reviewed. The median follow-up of patients still alive was 1.7 years (range 4 months to 4.5 years). The median survival from the date of repeat hepatic resection was 3.4 years with an estimated actuarial survival rate of 43 per cent at 4 years. These patients experienced no significant morbidity and the mortality rate was 5 per cent. Hepatic resection of metastatic colorectal carcinoma can produce long-term survival without prohibitive risk. These findings support an aggressive surgical approach for metastatic progression in the liver from colorectal carcinoma.
肝切除术是结直肠癌肝转移患者实现长期生存的唯一治疗方法。肝切除术的这种显著疗效促使人们努力扩大针对肝脏内疾病进展的手术方式。为了明确手术在疾病进展中的作用,我们回顾了个人经验及相关文献。对1983年至1991年间因肝脏孤立性疾病进展而接受肝切除术的21例患者进行了回顾性研究。仍存活患者的中位随访时间为1.7年(范围4个月至4.5年)。再次肝切除术后的中位生存期为3.4年,4年的估计精算生存率为43%。这些患者无明显并发症,死亡率为5%。转移性结直肠癌的肝切除术可实现长期生存且风险可控。这些发现支持对结直肠癌肝转移进展采取积极的手术治疗方法。